RespireRx Pharmaceuticals Inc (fka RSPI)

[atheroprevent]

>>The status of the SRT501 myeloma trial is currently described by trial organizers as “suspended” due to “unexpected safety events.” There is no further information as to the exact nature of the safety events or which patients were affected by the safety issues.<<
http://clinicaltrials.gov/ct2/show/NCT00920556

Sound familiar?

I think Sitris is now in Gsk's deep pocket. They are more focused on the easier low hanging fruit (diabetes). Neurodegenerative disease will be 10+ year project. JMO